Significance of heparin induced thrombocytopenia (HIT) in COVID-19: a systematic review and meta-analysis.
COVID-19
Heparin induced thrombocytopenia (HIT)
Heparinoids
SARS-CoV-2
Thrombocytopenia
Thrombosis
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
30
04
2023
medline:
13
7
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
ppublish
Résumé
Heparin-induced thrombocytopenia (HIT) occurs in approximately 3% of patients receiving heparinoids. About 30-75% of patients with type 2 of HIT develop thrombosis as a result of platelet activation. The most important clinical symptom is thrombocytopenia. Patients with severe COVID-19 are among those receiving heparinoids. This meta-analysis performed to picture the current knowledge and results of published studies in this field. Three search engines were searched and 575 papers were found. After evaluation, 37 articles were finally selected of which 13 studies were quantitatively analyzed. The pooled frequency rate of suspected cases with HIT in 13 studies with 11,241 patients was 1.7%. The frequency of HIT was 8.2% in the extracorporeal membrane oxygenation subgroup with 268 patients and 0.8% in the hospitalization subgroup with 10,887 patients. The coincidence of these two conditions may increase the risk of thrombosis. Of the 37 patients with COVID-19 and confirmed HIT, 30 patients (81%) were treated in the intensive care unit or had severe COVID-19. The most commonly used anticoagulants were UFH in 22 cases (59.4%). The median platelet count before treatment was 237 (176-290) x 10
Identifiants
pubmed: 37219826
doi: 10.1007/s11239-023-02827-5
pii: 10.1007/s11239-023-02827-5
pmc: PMC10203678
doi:
Substances chimiques
Heparin
9005-49-6
Heparinoids
0
Anticoagulants
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-252Subventions
Organisme : Mashhad University of Medical Sciences
ID : 4001161
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Boshkov LK et al (1993) Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 84(2):322–328
pubmed: 8398837
Fathi M (2018) Heparin-induced thrombocytopenia (HIT): identification and treatment pathways. Global cardiology science & practice. 2018(2)
Warkentin TE (1998) Clinical presentation of heparin-induced thrombocytopenia. in Seminars in hematology.
Warkentin TE et al (2013) Heparin-induced thrombocytopenia in medical surgical critical illness. Chest 144(3):848–858
pubmed: 23722881
Warkentin TE et al (2009) Studies of the immune response in heparin-induced thrombocytopenia blood. J Am Soc Hematol 113(20):4963–4969
Warkentin TE et al (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.
Newman PM, Chong BH (2000) Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4–heparin antibodies to platelets and the resultant platelet activation. Blood The Journal of the American Society of Hematology 96(1):182–187
Kanaan AO, Al-Homsi AS (2009) Heparin-induced thrombocytopenia: pathophysiology, diagnosis, and review of pharmacotherapy. J Pharm Pract 22(2):149–157
Warkentin TE et al (2008) Treatment and prevention of heparin-induced thrombocytopenia: american college of chest Physicians evidence-based clinical practice guidelines. Chest 133(6):340S–380S
pubmed: 18574270
Warkentin TE, Chong BH, Greinacher A (1998) Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 59(01):1–7
Mansouritorghabeh H (2015) Clinical and laboratory approaches to hemophilia A. Iran J Med Sci 40(3):194
pubmed: 25999618
pmcid: 4430880
Macera M et al (2020) Clinical presentation of COVID-19: case series and review of the literature. Int J Environ Res Public Health 17(14):5062
pubmed: 32674450
pmcid: 7399865
Wang D et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069
pubmed: 32031570
pmcid: 7042881
Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 395(10223):497–506
Rostami M, Mansouritorghabeh H (2020) D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol 13(11):1265–1275
pubmed: 32997543
Mehrdad R, Zahra K, Mansouritorghabeh H (2021) Hemostatic system (Fibrinogen level, D-Dimer, and FDP) in severe and Non-Severe patients With COVID-19: a systematic review and meta-Analysis Clinical and Applied Thrombosis/Hemostasis, 27: p. 10760296211010973
Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M (2021) High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis.Clinical and Experimental Medicine, : p.1–11
Al-Ani F, Chehade S, Lazo-Langner A (2020) Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res 192:152–160
pubmed: 32485418
pmcid: 7255332
Hippensteel JA et al (2020) Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiology-Lung Cell Mol Physiol 319(2):L211–L217
Shi C et al (2021) Comprehensive landscape of heparin therapy for COVID-19. Carbohydr Polym 254:117232
pubmed: 33357843
ATTACC A-a, Investigators R-C (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 385(9):790–802
Cook D et al (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 33(7):1565–1571
pubmed: 16003063
Ribic C et al (2009) Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. J Crit Care 24(2):197–205
pubmed: 19327323
Geerts WH et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and thrombolytic therapy. Chest 126(3):338S–400S
pubmed: 15383478
Kurtoğlu M et al (2003) Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie) Ulusal Travma ve Acil Cerrahi Dergisi = turkish. J Trauma Emerg Surgery: TJTES 9(1):37–44
Sholzberg M et al (2021) Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.bmj,375
Uaprasert N et al (2021) Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. Blood Adv 5(21):4521–4534
pubmed: 34543382
pmcid: 8455241
Daviet F et al (2020) Heparin-Induced Thrombocytopenia in severe COVID-19. Circulation 142(19):1875–1877
pubmed: 32990022
pmcid: 7643786
Lingamaneni P et al (2020) Heparin-induced thrombocytopenia in COVID-19. J Investig Med High Impact Case Rep 8:2324709620944091
pubmed: 32720827
pmcid: 7388103
Riker RR et al (2020) Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome. 4(5):936–941
Pivonello R et al (2021) Sex disparities in COVID-19 severity and outcome: are men weaker or women stronger? Neuroendocrinology 111(11):1066–1085
pubmed: 33242856
Uaprasert N, Tangcheewinsirikul N (2021) Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis. 5(21):4521–4534
Rostami M, Mansouritorghabeh H (2022) Trend of fluctuations of antithrombin in plasma of patients with COVID-19: a meta-analysis and systematic review. 15(8):747–755
Rostami M, Khoshnegah Z, Mansouritorghabeh H (2021) Hemostatic System (Fibrinogen Level, D-Dimer, and FDP) in Severe and Non-Severe Patients With COVID-19: A Systematic Review and Meta-Analysis 27: p. 10760296211010973
Mohammed HS et al (2022) Accelerated heparin-induced thrombocytopenia in a COVID-19 patient; a case report with literature review.Annals of Medicine and Surgery,78
Siddiqui NA et al (2021) Acute Limb Ischemia complicated by Heparin-Induced Thrombocytopenia in an asymptomatic COVID-19 patient. Cureus 13(7):e16162
pubmed: 34367772
pmcid: 8330877
Ogawa Y et al (2020) Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019. J Thromb Thrombolysis 50(4):1012–1014
pubmed: 32780355
pmcid: 7418284
Ionescu F et al (2021) Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. Eur J Haematol 106(2):165–174
pubmed: 33043484
Julian K, Bucher D, Jain R (2021) Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19.BMJ Case Reports, 14(5)
Sasaki K et al (2022) A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. J Infect Chemother 28(8):1208–1211
pubmed: 35570112
pmcid: 9091339
Ardiana M et al (2021) Case Report: heparin-induced thrombocytopenia during COVID-19 outbreak: the importance of scoring system in differentiating with sepsis-induced coagulopathy. F1000Research:10
May JE, Siniard RC, Marques M (2020) The challenges of diagnosing heparin-induced thrombocytopenia in patients with COVID-19 Research and Practice in Thrombosis and Haemostasis, 4(6): p. 1066–1067
Delrue M et al (2021) Contrast between prevalence of HIT antibodies and confirmed HIT in hospitalized COVID-19 patients: a prospective study with clinical implications. Thromb Haemost 121(07):971–975
pubmed: 33296940
Patell R et al (2020) Heparin induced thrombocytopenia antibodies in Covid-19. Am J Hematol 95(10):E295–E296
pubmed: 32658337
pmcid: 7405086
Warrior S et al (2020) Heparin Induced Thrombocytopenia in patients with COVID-19. Blood 136:3
Sartori M, Cosmi B (2021) Heparin-induced thrombocytopenia and COVID-19. Hematol Rep 13(1):8857
pubmed: 33747413
pmcid: 7970398
Huang CT et al (2020) Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19. Thromb Res 196:11–14
pubmed: 32810772
pmcid: 7834633
Lingamaneni P et al (2020) Heparin-Induced Thrombocytopenia in COVID-19Journal of Investigative Medicine High Impact Case Reports,8
Bidar F et al (2021) Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports. J Artif Organs 24(2):277–281
pubmed: 32789604
Riker RR et al (2020) Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome. Res Pract Thromb Haemostasis 4(5):936–941
Preti PS et al (2021) Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients. Thromb Res 203:33–35
pubmed: 33915353
pmcid: 8054612
Madala S, Krzyzak M, Dehghani S (2021) Is COVID-19 an independent risk factor for Heparin-Induced Thrombocytopenia? Cureus 13(2):e13425
pubmed: 33758713
pmcid: 7978146
Soliman S, Ghaly M (2022) Ischemic stroke and bilateral pulmonary embolism in COVID-19: COVID-Associated Coagulopathy or Heparin-Induced Thrombocytopenia. J Hematol 11(1):40–44
pubmed: 35356633
pmcid: 8929198
Murakami Y et al (2022) Ischemic stroke due to heparin-induced Thrombocytopenia during severe COVID-19 infection. Intern Med
Lazaro-Garcia A et al (2022) A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report. Hematology 27(1):318–321
pubmed: 35231200
Shiuan E et al (2022) Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection.Journal of Thrombosis and Thrombolysis, : p.5
Zyani A et al (2021) A rare case of intracerebral hemorrhage complicating heparin-induced thrombocytopenia in a COVID-19 patient. Annals of Medicine and Surgery, p 72
Turshudzhyan A (2020) SARS-CoV2 induced pulmonary embolism and complications from anticoagulation.Respiratory Medicine Case Reports,31
Tran M et al (2020) SARS-CoV-2 and pulmonary embolism: who stole the platelets? Thromb J 18(1):4
Phan XT et al (2020) Suspected heparin-induced thrombocytopenia in a COVID-19 patient on extracorporeal membrane oxygenation support: a case report. Thromb J 18(1):37
pubmed: 33317566
pmcid: 7734386
Benge EJ, McWhorter Y (2022) Triple threat: bilateral renal artery thrombosis and heparin induced thrombocytopenia in a patient with COVID-19, a case report.Journal of Emergency and Critical Care Medicine,6
Brodard J et al (2021) COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost 19(5):1294–1298
pubmed: 33550713
Pascreau T et al (2021) The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis. Clin Chem Lab Med 59(11):E405–E408
pubmed: 34187132
Arachchillage DJ et al (2022) Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. Br J Haematol 196(3):566–576
pubmed: 34622443
Daviet F et al (2021) Impact of obesity on survival in COVID-19 ARDS patients receiving ECMO: results from an ambispective observational cohort.Annals of Intensive Care, 11(1)
Tabatabai A et al (2021) Mortality Risk Assessment in COVID-19 venovenous extracorporeal membrane oxygenation. Ann Thorac Surg 112(6):1983–1989
pubmed: 33485917
pmcid: 7825896
Lonati PA et al (2022) Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination. Rmd Open 8(1):5
Durak K et al (2021) Thromboembolic and bleeding events in COVID-19 patients receiving extracorporeal membrane oxygenation. Thorac Cardiovasc Surgeon 69(6):526–536
Al-Samkari H et al (2021) Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with covid-19. Ann Intern Med 174(5):622–632
pubmed: 33493012
Parzy G et al (2020) Venous thromboembolism events following venovenous extracorporeal membrane oxygenation for severe Acute Respiratory Syndrome Coronavirus 2 based on CT scans. Crit Care Med 48(10):e971–e975
pubmed: 32618700
Helms J et al (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46(6):1089–1098
pubmed: 32367170
pmcid: 7197634
Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19.New England Journal of Medicine, 385(9): p.790–802